Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Strategies for studying the ligand binding site of GPCRs: photoaffinity labeling of the VPAC1 receptor, a prototype of class B GPCRs.

Couvineau A, Tan YV, Ceraudo E, Laburthe M.

Methods Enzymol. 2013;520:219-37. doi: 10.1016/B978-0-12-391861-1.00010-1.

PMID:
23332702
2.

The VPAC1 receptor: structure and function of a class B GPCR prototype.

Couvineau A, Ceraudo E, Tan YV, Nicole P, Laburthe M.

Front Endocrinol (Lausanne). 2012 Nov 16;3:139. doi: 10.3389/fendo.2012.00139. eCollection 2012.

3.

[How to turn a silent proapoptotic gene in a potent antitumoral target in colorectal cancer].

Laburthe M.

Med Sci (Paris). 2012 Mar;28(3):272-3. doi: 10.1051/medsci/2012283015. Epub 2012 Apr 6. French. No abstract available.

4.

Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction.

Ceraudo E, Hierso R, Tan YV, Murail S, Rouyer-Fessard C, Nicole P, Robert JC, Jamin N, Neumann JM, Robberecht P, Laburthe M, Couvineau A.

FASEB J. 2012 May;26(5):2060-71. doi: 10.1096/fj.11-196444. Epub 2012 Jan 30.

PMID:
22291440
5.

Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA, Said SI.

Br J Pharmacol. 2012 May;166(1):4-17. doi: 10.1111/j.1476-5381.2012.01871.x. Review.

6.

VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.

Couvineau A, Laburthe M.

Br J Pharmacol. 2012 May;166(1):42-50. doi: 10.1111/j.1476-5381.2011.01676.x. Review.

7.

The family B1 GPCR: structural aspects and interaction with accessory proteins.

Couvineau A, Laburthe M.

Curr Drug Targets. 2012 Jan;13(1):103-15. Review.

PMID:
21777182
8.

VIP blockade leads to microcephaly in mice via disruption of Mcph1-Chk1 signaling.

Passemard S, El Ghouzzi V, Nasser H, Verney C, Vodjdani G, Lacaud A, Lebon S, Laburthe M, Robberecht P, Nardelli J, Mani S, Verloes A, Gressens P, Lelièvre V.

J Clin Invest. 2011 Aug;121(8):3071-87. doi: 10.1172/JCI43824.

9.

The orexin receptor OX(1)R in colon cancer: a promising therapeutic target and a new paradigm in G protein-coupled receptor signalling through ITIMs.

Laburthe M, Voisin T.

Br J Pharmacol. 2012 Mar;165(6):1678-1687. doi: 10.1111/j.1476-5381.2011.01510.x. Review.

10.

Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: an openable gate to apoptosis.

Voisin T, El Firar A, Fasseu M, Rouyer-Fessard C, Descatoire V, Walker F, Paradis V, Bedossa P, Henin D, Lehy T, Laburthe M.

Cancer Res. 2011 May 1;71(9):3341-51. doi: 10.1158/0008-5472.CAN-10-3473. Epub 2011 Mar 17.

11.

Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease.

Fasseu M, Tréton X, Guichard C, Pedruzzi E, Cazals-Hatem D, Richard C, Aparicio T, Daniel F, Soulé JC, Moreau R, Bouhnik Y, Laburthe M, Groyer A, Ogier-Denis E.

PLoS One. 2010 Oct 5;5(10). pii: e13160. doi: 10.1371/journal.pone.0013160.

12.

VPAC1 receptor binding site: contribution of photoaffinity labeling approach.

Couvineau A, Ceraudo E, Tan YV, Laburthe M.

Neuropeptides. 2010 Apr;44(2):127-32. doi: 10.1016/j.npep.2009.11.008. Epub 2009 Dec 23. Review.

PMID:
20031208
13.

Orexins/hypocretins and orexin receptors in apoptosis: a mini-review.

Laburthe M, Voisin T, El Firar A.

Acta Physiol (Oxf). 2010 Mar;198(3):393-402. doi: 10.1111/j.1748-1716.2009.02035.x. Epub 2009 Aug 28.

PMID:
19719798
14.

Discovery of a functional immunoreceptor tyrosine-based switch motif in a 7-transmembrane-spanning receptor: role in the orexin receptor OX1R-driven apoptosis.

El Firar A, Voisin T, Rouyer-Fessard C, Ostuni MA, Couvineau A, Laburthe M.

FASEB J. 2009 Dec;23(12):4069-80. doi: 10.1096/fj.09-131367. Epub 2009 Aug 6.

PMID:
19661287
15.

Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor.

Bourgault S, Vaudry D, Ségalas-Milazzo I, Guilhaudis L, Couvineau A, Laburthe M, Vaudry H, Fournier A.

J Med Chem. 2009 May 28;52(10):3308-16. doi: 10.1021/jm900291j.

PMID:
19413310
16.

Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase.

Gratio V, Walker F, Lehy T, Laburthe M, Darmoul D.

Int J Cancer. 2009 Apr 1;124(7):1517-25. doi: 10.1002/ijc.24070.

17.

PACAP prevents toxicity induced by cisplatin in rat and primate neurons but not in proliferating ovary cells: involvement of the mitochondrial apoptotic pathway.

Aubert N, Vaudry D, Falluel-Morel A, Desfeux A, Fisch C, Ancian P, de Jouffrey S, Le Bigot JF, Couvineau A, Laburthe M, Fournier A, Laudenbach V, Vaudry H, Gonzalez BJ.

Neurobiol Dis. 2008 Oct;32(1):66-80. doi: 10.1016/j.nbd.2008.06.014. Epub 2008 Jul 3.

PMID:
18652895
18.

The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor.

Ceraudo E, Tan YV, Nicole P, Couvineau A, Laburthe M.

J Mol Neurosci. 2008 Nov;36(1-3):245-8. doi: 10.1007/s12031-008-9073-7. Epub 2008 Jul 3.

PMID:
18597186
19.

Production and purification of large quantities of the functional N-terminal ectodomain of human VPAC1 receptor.

Couvineau A, Robert JC, Ramdani T, Lacapère JJ, Rouyer-Fessard C, Laburthe M.

J Mol Neurosci. 2008 Nov;36(1-3):249-53. doi: 10.1007/s12031-008-9072-8. Epub 2008 Jul 1.

PMID:
18592417
20.

Class-B GPCR activation: is ligand helix-capping the key?

Neumann JM, Couvineau A, Murail S, Lacapère JJ, Jamin N, Laburthe M.

Trends Biochem Sci. 2008 Jul;33(7):314-9. doi: 10.1016/j.tibs.2008.05.001. Epub 2008 Jun 12.

PMID:
18555686
21.

Biological and structural analysis of truncated analogs of PACAP27.

Bourgault S, Vaudry D, Guilhaudis L, Raoult E, Couvineau A, Laburthe M, Ségalas-Milazzo I, Vaudry H, Fournier A.

J Mol Neurosci. 2008 Nov;36(1-3):260-9. doi: 10.1007/s12031-008-9081-7. Epub 2008 May 13.

PMID:
18473187
22.

Novel stable PACAP analogs with potent activity towards the PAC1 receptor.

Bourgault S, Vaudry D, Botia B, Couvineau A, Laburthe M, Vaudry H, Fournier A.

Peptides. 2008 Jun;29(6):919-32. doi: 10.1016/j.peptides.2008.01.022. Epub 2008 Feb 13.

PMID:
18353507
23.

A hallmark of immunoreceptor, the tyrosine-based inhibitory motif ITIM, is present in the G protein-coupled receptor OX1R for orexins and drives apoptosis: a novel mechanism.

Voisin T, El Firar A, Rouyer-Fessard C, Gratio V, Laburthe M.

FASEB J. 2008 Jun;22(6):1993-2002. doi: 10.1096/fj.07-098723. Epub 2008 Jan 15.

PMID:
18198212
24.

PAR-2 activation increases human intestinal mucin secretion through EGFR transactivation.

Jarry A, Dorso L, Gratio V, Forgue-Lafitte ME, Laburthe M, Laboisse CL, Darmoul D.

Biochem Biophys Res Commun. 2007 Dec 21;364(3):689-94. Epub 2007 Oct 22.

PMID:
18028876
26.

Involvement of VIP and PACAP in neonatal brain lesions generated by a combined excitotoxic/inflammatory challenge.

Favrais G, Couvineau A, Laburthe M, Gressens P, Lelievre V.

Peptides. 2007 Sep;28(9):1727-37. Epub 2007 Jun 28.

PMID:
17683829
27.

Orexins control intestinal glucose transport by distinct neuronal, endocrine, and direct epithelial pathways.

Ducroc R, Voisin T, El Firar A, Laburthe M.

Diabetes. 2007 Oct;56(10):2494-500. Epub 2007 Jul 12.

28.

Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology.

Laburthe M, Couvineau A, Tan V.

Peptides. 2007 Sep;28(9):1631-9. Epub 2007 May 22. Review.

PMID:
17574305
29.

[MicroRNAs and intestinal pathophysiology].

Ogier-Denis E, Fasseu M, Vandewalle A, Laburthe M.

Med Sci (Paris). 2007 May;23(5):509-14. Review. French.

30.

Characterization of the new photoaffinity probe (Bz2-K24)-VIP.

Tan YV, Couvineau A, Lacapere JJ, Laburthe M.

Ann N Y Acad Sci. 2006 Jul;1070:575-80.

PMID:
16888228
31.

Expression and GTP sensitivity of peptide histidine isoleucine high-affinity-binding sites in rat.

Debaigt C, Meunier AC, Goursaud S, Montoni A, Pineau N, Couvineau A, Laburthe M, Muller JM, Janet T.

Ann N Y Acad Sci. 2006 Jul;1070:215-9.

PMID:
16888169
32.

The human VPAC1 receptor: identification of the N-terminal ectodomain as a major VIP-binding site by photoaffinity labeling and 3D modeling.

Couvineau A, Tan YV, Ceraudo E, Lacapère JJ, Murail S, Neumann JM, Laburthe M.

Ann N Y Acad Sci. 2006 Jul;1070:205-9.

PMID:
16888167
33.

Spatial approximation between the C-terminus of VIP and the N-terminal ectodomain of the VPAC1 receptor.

Ceraudo E, Tan YV, Couvineau A, Lacapere JJ, Laburthe M.

Ann N Y Acad Sci. 2006 Jul;1070:180-4.

PMID:
16888162
34.

Orexin-induced apoptosis: the key role of the seven-transmembrane domain orexin type 2 receptor.

Voisin T, Firar AE, Avondo V, Laburthe M.

Endocrinology. 2006 Oct;147(10):4977-84. Epub 2006 Jul 20.

PMID:
16857748
35.

Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling.

Tan YV, Couvineau A, Murail S, Ceraudo E, Neumann JM, Lacapère JJ, Laburthe M.

J Biol Chem. 2006 May 5;281(18):12792-8. Epub 2006 Mar 6.

36.
37.
38.

Orexins acting at native OX(1) receptor in colon cancer and neuroblastoma cells or at recombinant OX(1) receptor suppress cell growth by inducing apoptosis.

Rouet-Benzineb P, Rouyer-Fessard C, Jarry A, Avondo V, Pouzet C, Yanagisawa M, Laboisse C, Laburthe M, Voisin T.

J Biol Chem. 2004 Oct 29;279(44):45875-86. Epub 2004 Aug 13.

40.
41.

Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.

Marie JC, Rouyer-Fessard C, Couvineau A, Nicole P, Devaud H, El Benna J, Laburthe M.

Mol Pharmacol. 2003 Dec;64(6):1565-74.

PMID:
14645688
42.

Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor.

Tan YV, Couvineau A, Van Rampelbergh J, Laburthe M.

J Biol Chem. 2003 Sep 19;278(38):36531-6. Epub 2003 Jun 13.

44.
45.

Orexins and their receptors: structural aspects and role in peripheral tissues.

Voisin T, Rouet-Benzineb P, Reuter N, Laburthe M.

Cell Mol Life Sci. 2003 Jan;60(1):72-87. Review.

PMID:
12613659
46.

VPAC receptors for VIP and PACAP.

Laburthe M, Couvineau A, Marie JC.

Receptors Channels. 2002;8(3-4):137-53. Review.

PMID:
12529932
47.

Novel receptor partners and function of receptor activity-modifying proteins.

Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A, Kuwasako K, Tilakaratne N, Sexton PM.

J Biol Chem. 2003 Jan 31;278(5):3293-7. Epub 2002 Nov 21.

48.

Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP.

Laburthe M, Couvineau A.

Regul Pept. 2002 Oct 15;108(2-3):165-73. Review.

PMID:
12220741
49.

Human VPAC1 receptor selectivity filter. Identification of a critical domain for restricting secretin binding.

Du K, Couvineau A, Rouyer-Fessard C, Nicole P, Laburthe M.

J Biol Chem. 2002 Oct 4;277(40):37016-22. Epub 2002 Jul 19.

50.

Trypsin is produced by and activates protease-activated receptor-2 in human cancer colon cells: evidence for new autocrine loop.

Ducroc R, Bontemps C, Marazova K, Devaud H, Darmoul D, Laburthe M.

Life Sci. 2002 Feb 8;70(12):1359-67.

PMID:
11883712

Supplemental Content

Loading ...
Support Center